Literature DB >> 15072961

Endothelin-1-induced responses in isolated mouse vessels: the expression and function of receptor types.

Yingbi Zhou1, Wessel P Dirksen, Jay L Zweier, Muthu Periasamy.   

Abstract

Mice have been increasingly used as models for investigating cardiovascular diseases. However, the responsiveness of mouse vasculature to endothelin (ET)-1 has not been clearly established. The goal of this study was to determine the role of ET receptors (ET(A) and ET(B)) in mouse vessels using isometric force measurements. Results showed that in the abdominal aorta ET-1 induced a concentration-dependent contraction (EC(50): 1.4 nM) with maximum reaching 89.5 +/- 4.9% (10 nM) of that induced by 60 mM K(+) [with nitric oxide synthase (NOS) inhibitor N(omega)-nitro-l-arginine methyl ester (l-NAME)]. However, in the thoracic aorta or the carotid artery, ET-1 was poorly effective. RT-PCR revealed that in the endothelium-denuded abdominal aorta, the PCR product for ET(B) receptors was very low compared with ET(A). Similarly in tissues treated with l-NAME, the ET(B) receptor-specific agonist sarafotoxin 6c (S6c; 100 nM) induced only a minimal contraction (<5%). Meanwhile, the ET(A) antagonist BQ-123 (1 microM) completely inhibited the maximum ET-1 (10 nM) contractile response. Furthermore, we found that in the abdominal aorta that had not been treated with l-NAME, ET-1-induced contraction significantly decreased. However, in such specimens, S6c was unable to induce any relaxation on phenylephrine-induced contraction. These results indicate that the role of ET receptors differs considerably among mouse vessels. In the abdominal aorta, ET(A) receptor mediates a potent vasoconstrictor response, whereas ET(B) has, if any, only a minimal functional presence. Also, our data suggest that ET-1 might involve a NOS-dependent vasodilation in the abdominal aorta, which remains to be further defined.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15072961     DOI: 10.1152/ajpheart.01170.2003

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  7 in total

Review 1.  The vascular endothelin system in hypertension--recent patents and discoveries.

Authors:  Meri M Hynynen; Raouf A Khalil
Journal:  Recent Pat Cardiovasc Drug Discov       Date:  2006-01

Review 2.  Modulators of the vascular endothelin receptor in blood pressure regulation and hypertension.

Authors:  Raouf A Khalil
Journal:  Curr Mol Pharmacol       Date:  2011-11       Impact factor: 3.339

3.  Endothelial overexpression of endothelin-1 modulates aortic, carotid, iliac and renal arterial responses in obese mice.

Authors:  Oliver Baretella; Sookja K Chung; Aimin Xu; Paul M Vanhoutte
Journal:  Acta Pharmacol Sin       Date:  2017-02-20       Impact factor: 6.150

4.  Mouse model of focal cerebral ischemia using endothelin-1.

Authors:  Nobutaka Horie; Anne-Lise Maag; Scott A Hamilton; Hideo Shichinohe; Tonya M Bliss; Gary K Steinberg
Journal:  J Neurosci Methods       Date:  2008-06-25       Impact factor: 2.390

5.  Chemerin connects fat to arterial contraction.

Authors:  Stephanie W Watts; Anne M Dorrance; Mark E Penfold; Jillian L Rourke; Christopher J Sinal; Bridget Seitz; Timothy J Sullivan; Trevor T Charvat; Janice M Thompson; Robert Burnett; Gregory D Fink
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-04-04       Impact factor: 8.311

6.  High-fat diet induces obesity in adult mice but fails to develop pre-penile and penile vascular dysfunction.

Authors:  Michael R Odom; Trevor C Hunt; Elena S Pak; Johanna L Hannan
Journal:  Int J Impot Res       Date:  2021-05-04       Impact factor: 2.408

7.  Interleukin-10 attenuates vascular responses to endothelin-1 via effects on ERK1/2-dependent pathway.

Authors:  Fernanda R C Giachini; Saiprasad M Zemse; Fernando S Carneiro; Victor V Lima; Zidonia N Carneiro; Glaucia E Callera; Adviye Ergul; R Clinton Webb; Rita C Tostes
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-12-12       Impact factor: 4.733

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.